News Search Results
Oct 23, 2025, 08:45 ET Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Spartan Capital Securities Second Annual
More news about: Anixa Biosciences, Inc.
Oct 23, 2025, 08:33 ET BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
About BridGene Biosciences BridGene is a biotechnology company focused on discovering and developing innovative small molecules that drug traditionally undruggable targets, providing new paths to treat
More news about: BridGene Biosciences
Oct 23, 2025, 08:30 ET Improve Clinical Trial Delivery by Leveraging AI Forecasting Tools, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 23, 2025, 08:30 ET Drug Compendia: Practical Strategies to Bridge Evidence and Payer Coverage, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 23, 2025, 08:00 ET Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- Vial, a clinical-stage biotechnology company, announced that it is initiating the Phase 1 trial for a novel INHBE (Activin E) siRNA, which is being developed as a potentially best-in-class
More news about: Vial
Oct 23, 2025, 08:00 ET Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
[email protected] About STRM.BIOBased in Cambridge, MA, STRM.BIO is a pre-clinical, venture-backed biotechnology company leveraging extracellular vesicles as a platform to develop and deliver targeted genetic medicines in vivo that are safe for repeat
More news about: Ginkgo Bioworks
Oct 23, 2025, 07:00 ET HanchorBio's Novel CD47-SIRPα Therapeutic HCB101 Accepted for Publication in Prestigious Journal of Hematology & Oncology
SAN FRANCISCO, Oct. 23, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that its manuscript describing the discovery and preclinical development of
More news about: HanchorBio Inc.
Oct 23, 2025, 06:55 ET Phase Change Materials Market worth $1,639.71 million by 2030 - Exclusive Report by MarketsandMarkets™
cooling loads, and lower energy costs. The rapid expansion of cold chain logistics, especially for pharmaceuticals, vaccines, perishable foods, and biotechnology products, has further accelerated PCM adoption, as these materials ensure stable temperatures during transport and storage while minimizing spoilage
More news about: MarketsandMarkets
Oct 23, 2025, 06:00 ET Swiss Rockets and Squirro Announce Strategic Partnership to Accelerate AI Transformation in Biotechnology
Oct. 23, 2025 /PRNewswire/ -- Swiss Rockets AG, a Basel-based biotechnology incubator and accelerator, and Squirro AG, a leading Swiss enterprise AI company,
More news about: Squirro
Oct 23, 2025, 06:00 ET Future Origins Demonstrates Large Scale Production of Nalo™
"Future Origins is a powerful demonstration of how scientific innovation can enhance our supply chain, bringing together breakthrough biotechnology with scalable execution," said Richard Slater, Chief R&D Officer at Unilever. "It's a milestone that reinforces our belief that through leading-edge
More news about: Future Origins
Oct 22, 2025, 23:30 ET MGI Tech partners with Eva Holding Group to enhance the accuracy of disease monitoring
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and full spectrum of digital equipment and systems for precision medicine, agriculture,
More news about: MGI TECH
Oct 22, 2025, 16:05 ET BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET
archived on the site for one week following the call. About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San
More news about: BioMarin Pharmaceutical Inc.
Oct 22, 2025, 14:08 ET Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
JUPITER, Fla., Oct. 22, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Myosin Therapeutics Inc.
Oct 22, 2025, 12:00 ET SynbioTech Brings Taiwan's Biotech Excellence to the Global Stage with TWK10® for Muscle Performance and Healthy Aging
Oct. 22, 2025 /PRNewswire/ -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company from Taiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically
More news about: SYNBIO TECH INC.
Oct 22, 2025, 11:30 ET SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
www.merlinmelanomatest.com. About SkylineDx SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Oct 22, 2025, 11:16 ET UpTerra brings on new Chief Science Officer with Shiv Tiwari, Ph.D., former GreenVenus CEO and CTO
transformation in hardy corn varieties, which helped advance maize product development in the seed industry.He is a seasoned biotechnology executive, recently serving as CEO/CTO at GreenVenus. There, he led the startup from concept to commercial readiness, leading the charge on regulatory
More news about: UpTerra
Oct 22, 2025, 11:10 ET Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™
Oct. 22, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Oct 22, 2025, 10:01 ET US Premium Beauty and Personal Care Market Eyes USD 56.47 Billion by 2032 | Steady 1.97% CAGR Reflects Growing Preference for Premium Skincare & Cosmetics - MarkNtel Advisors
high-end products conveniently and enhancing brand visibility through direct-to-consumer strategies. Biotechnology Innovations: Advancements in ingredient research, particularly biotechnological developments, are enhancing product efficacy and safety, setting
More news about: MarkNtel Advisors
Oct 22, 2025, 08:33 ET Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial Activity of Bisphosphocin® Class Against Resistant Pathogens
Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin®
More news about: Lakewood-Amedex Inc.
Oct 22, 2025, 08:30 ET Accelerating Drug Discovery from Virtual Screening to Lead Optimization, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 22, 2025, 08:30 ET Overcoming Late-Stage Formulations & Manufacturing Challenges with KinetiSol Technology, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 22, 2025, 08:30 ET The Evolution of Precision Medicine in Age-Related Neurological Diseases, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 22, 2025, 08:00 ET Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Oct 22, 2025, 07:39 ET EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics
Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with serious immunological and cancer-related diseases Financing was co-led by EQT Life Sciences and Nextech, with participation
More news about: EQT
Oct 22, 2025, 07:00 ET Nanoscope Therapeutics Announces Durable 3-Year Vision Improvements from REMAIN Study of MCO-010 in Retinitis Pigmentosa
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics